Steven Dickman

This highly interactive and extended workshop offers a deep dive into the GLP-1 landscape, moving beyond clinical data to focus squarely on market opportunity, investor perception, and financial strategy. Attendees will gain practical insights on the most promising “Future of GLP-1” opportunities – from multi-agonists to neurobiology and novel indications – and learn how to translate these scientific concepts into compelling, fundable, and profitable business plans that capture commercial interest. The session integrates real-time audience surveys, displaying live results to benchmark audience sentiment against expert opinion, ensuring maximum engagement and direct relevance.

This workshop will gather experts to discuss:

• Evaluating the true peak sales potential and valuation drivers for next-generation GLP- 1s, including the financial impact of expanding into key indications like MASH, CKD and beyond to neurological disorders and addiction
• Utilizing interactive audience polls to assess which next-frontier innovations (e.g., muscle preservation, oral formulation, neurobiology) investors are actively prioritizing for the next five years
• Analyzing recent M&A and licensing activity in the cardiometabolic space to project which asset types and company profiles are most likely to be acquisition targets and the specific metrics currently driving those deals
• Demonstrating how companies can weave complex GLP-1 mechanisms into an attractive and robust business plan that secures executive and investor buy-in
• Tailoring funding roadmaps and communication strategies to attract different pools of capital (Venture vs. Public Equity) while navigating the stringent non-clinical criteria of investor due diligence